Item 2.01 Completion of Acquisition or Disposition of Assets
On
As part of the Disposition, pursuant to the Disposition Agreement, certain
shareholders of the Company transferred an aggregate of 350,000 shares of the
Company's currently outstanding common stock, par value
The foregoing description of the Disposition Agreement is qualified in its entirety by reference to the Disposition Agreement filed as Exhibit 10.1 to this Current Report.
Item 7.01. Regulation FD Disclosure
On
The Company intends to use the Presentation in presentations to investors and
analysts from time to time in the future. The furnishing of the information in
this Current Report is not intended to, and does not, constitute a determination
by the Company that the information in this Current Report is material or
complete, or that investors should consider this information before making an
investment decision with respect to any security of the Company. The information
in the materials is presented as of
The information in Item 7.01 of this Current Report shall not be deemed to be "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Agreements Relating to the Transfer of the Mioxal Product, dated as 10.1 ofNovember 7, 2022 , by and betweenInnovation1 Biotech Inc. andIngenius Biotech S.L . 99.1Innovation1 Biotech Inc. Presentation datedNovember 14, 2022 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) 2
© Edgar Online, source